CYP2C19 and Stroke: The authors described that ABCB1 C3435T and CYP2C19 genotypes were significant, independent predictors of the primary endpoint, and that the 47% of the population, who were either CYP2C19 reduced-function allele carriers, ABCB1 3435 TT homozygotes, or both were at significantly increased risk of cardiovascular death, myocardial infarction, or stroke.